Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
Add more filters










Publication year range
1.
Int J Surg Case Rep ; 67: 82-85, 2020.
Article in English | MEDLINE | ID: mdl-32044563

ABSTRACT

INTRODUCTION: Deep pelvic lymph node dissection for cancer may result in incisional inguinal hernias. We present a case report of successful laparoscopic trans-peritoneal repair of a large ventral inguinal hernia that developed following ileo-inguinal lymph node dissection (CLND) for melanoma. CASE PRESENTATION: A successful 3 port laparoscopic trans-peritoneal procedure was performed on a 56-year-old female for the repair of a left inguinal hernia, developed 13 months following CLND for melanoma. The large oval 18 × 14 cm inguinal defect, with superior margins bordering the conjoint tendon and inferior margins bordering the ileo-psoas muscle, femoral vessels and nerve, was not closed in order to avoid excessive tension and was repaired by fixing a 25 × 20 cm intra-peritoneal mesh to abdominal borders at superior and lateral margins with permanent fasteners and at the inferior margin by a cyanoacrylate-glued overlap to protect femoral vessels and nerves from damage. No hernia recurrence was observed 8 months following this procedure. DISCUSSION: Incisional inguinal hernias, following CLND, are rare but present a challenge to surgeons due to the difficulty in identifying both anatomical plains and safe sites for stable repair. CONCLUSIONS: We report a laparoscopic trans-peritoneal approach for the safe, reproducible and efficacious repair of incisional inguinal hernias that result from CLND. In our opinion prevention of hernia recurrence can be achieved by a intraperitoneal large mesh fixed at superior and lateral margin borders with permanent fasteners and using cyanoacrylate glue to overlap inferior margin borders in order to prevent vessels and/or nerve injury.

2.
Int J Surg Case Rep ; 61: 4-8, 2019.
Article in English | MEDLINE | ID: mdl-31302319

ABSTRACT

INTRODUCTION: Merkel cell carcinoma (MCC) is a rare, neuroendocrine skin tumor, with high frequency of locoregional recurrence, metastases, and poor prognosis. Locoregional MCC recurrence in the extremities can pose considerable treatment challenges. We report a case of long-term survival in a female patient with recurrent MCC of the leg, treated with surgery and locoregional chemotherapy. PRESENTATION OF CASE: A 73-year-old female with cirrhosis and hepatitis C, developed cutaneous MCC in the left inferior limb. This patient initially received surgical treatment, with subsequent negative sentinel lymph-node biopsy in another center, one-month prior recovery in our department, and arrived with 4 new limb nodules, cranially to the previously treated area, without distant metastases or inguinal lymph node recurrence. This patient was not eligible for immunotherapy due to active hepatitis upon treatment with NS5B inhibitors, or eligible for systemic chemotherapy or radiotherapy due to severe neutropenia and was, therefore, subjected to surgical resection combined with Isolated Pelvic and Limb Perfusion (IPLP) with Melphalan. Histological evaluation confirmed MCC diagnosis and during the following 4 months, she developed further locoregional recurrences with homolateral inguinal lymph node involvement and was subjected to two additional rounds of surgery plus IPLP. DISCUSSION: All procedures were tolerated, systemic toxicities were temporary and subsequent clinical and radiological follow-up, following the last combined treatment, indicated that this patient was still alive and disease-free, at 56 months. CONCLUSION: In this case, surgery combined with locoregional Melphalan chemotherapy was an effective and repeatable treatment for recurrent MMC and resulted in unexpected long-term survival.

3.
J Sci Med Sport ; 20(5): 451-458, 2017 May.
Article in English | MEDLINE | ID: mdl-26117159

ABSTRACT

OBJECTIVES: To examine the evidence for effect of restricted ankle dorsiflexion range of motion on lower-extremity landing mechanics. DESIGN: Literature review. METHODS: Systematic search of the literature. Articles critiqued by two reviewers. RESULTS: Six studies were identified that investigated the effect of restricted DF ROM on landing mechanics. Overall, results suggest that landing mechanics are altered with restricted DF ROM, but studies disagree as to the particular mechanical variables affected. CONCLUSIONS: There is evidence that restricted dorsiflexion range of motion may alter lower-extremity landing mechanics in a manner, which predisposes athletes to injury. Interpretation of results was made difficult by the variation in landing tasks investigated and the lack studies investigating sport-specific landing tasks. The focus of studies on specific mechanical variables rather than mechanical patterns and the analysis of pooled data in the presence of different compensation strategies between participants also made interpretation difficult. These areas require further research.


Subject(s)
Ankle Joint/physiology , Lower Extremity/physiology , Weight-Bearing , Athletic Injuries/etiology , Biomechanical Phenomena , Female , Humans , Male , Range of Motion, Articular/physiology
4.
Cell Death Discov ; 2: 16004, 2016.
Article in English | MEDLINE | ID: mdl-27551499

ABSTRACT

We report a novel pro-apoptotic function for nerve growth factor (NGF) and its tropomyosin-related kinase A (TrkA) receptor in sensitizing TRAIL (TNF-related apoptotis-inducing ligand)-resistant SH-SY5Y neuroblastoma (NB) cells to TRAIL-induced apoptosis, resulting in the abrogation of anchorage-independent tumourigenic growth in vitro. We show that the TRAIL-resistant SH-SY5Y phenotype is cFLIP (cellular FLICE-like inhibitory protein) dependent and not due to low-level functional TRAIL receptor or caspase expression or an inhibitory equilibrium between functional and decoy TRAIL receptors or B-cell lymphoma 2 (Bcl-2) and BH3-only (Bcl-2 homology domain 3-only) family proteins. NGF sensitization of SH-SY5Y cells to TRAIL-induced apoptosis was dependent upon TrkA expression, activation and subsequent sequestration of cFLIP. This reduces cFLIP recruitment to TRAIL-activated death receptors and increases the recruitment of caspase-8, leading to TRAIL-induced, caspase-dependent, type II apoptosis via the intrinsic mitochondrial pathway. This effect was temporary, inhibited within 6 h by nuclear factor-κ binding (NF-κB)-mediated increase in myeloid cell leukaemia-1 (Mcl-1) expression, abrogated by transient cFLIP or B-cell lymphoma-extra large (Bcl-xL) overexpression and optimized by NF-κB and Mcl-1 inhibitors. This novel mechanism adds an important pro-apoptotic immunological dimension to NGF/TrkA interaction that may not only help to explain the association between TrkA expression, better prognosis and spontaneous remission in NB, but also provides a novel potential pro-apoptotic therapeutic use for NGF, TRAIL and inhibitors of NF-κB and/or Mcl-1 in favourable and unfavourable NBs that express TrkA and exhibit cFLIP-mediated TRAIL resistance.

6.
J Sci Med Sport ; 19(7): 531-40, 2016 Jul.
Article in English | MEDLINE | ID: mdl-26292609

ABSTRACT

OBJECTIVES: To examine the evidence for effect of ankle bracing on lower-extremity landing biomechanics. DESIGN: Literature review. METHODS: Systematic search of the literature on EBSCO health databases. Articles critiqued by two reviewers. RESULTS: Ten studies were identified which investigated the effect of ankle bracing on landing biomechanics. Overall results suggest that landing biomechanics are altered with some brace types but studies disagree as to the particular variables affected. CONCLUSIONS: There is evidence that ankle bracing may alter lower-extremity landing biomechanics in a manner which predisposes athletes to injury. The focus of studies on specific biomechanical variables rather than biomechanical patterns, analysis of pooled data means in the presence of differing landing styles between participants, variation in landing-tasks investigated in different studies, and lack of studies investigating goal-directed sport-specific landing tasks creates difficulty in interpreting results. These areas require further research.


Subject(s)
Ankle Joint/physiology , Athletic Injuries/prevention & control , Braces/adverse effects , Lower Extremity/physiology , Biomechanical Phenomena , Female , Humans , Male , Range of Motion, Articular
7.
Oncogene ; 28(46): 4075-94, 2009 Nov 19.
Article in English | MEDLINE | ID: mdl-19734938

ABSTRACT

Hsp90 chaperones stabilize many tyrosine kinases including several oncogenes, which are inhibited or induced to degrade by the Hsp90 inhibitor geldanamycin (GA). As a consequence, GA has been developed for future chemotherapeutic use in several tumour types including neuroblastoma (NB). Alternative splicing of the neurotrophin receptor tyrosine kinase TrkA may have a pivotal function in regulating NB behaviour, with reports suggesting that tumour-suppressing signals from TrkA may be converted to oncogenic signals by stress-regulated alternative TrkAIII splicing. Within this context, it is important to know whether Hsp90 interacts with TrkA variants in NB cells and how GA influences this. Here, we report that both TrkAI and TrkAIII are Hsp90 clients in human NB cells. TrkAI exhibits GA-sensitive interaction with Hsp90 required for receptor endoplasmic reticulum export, maturation, cell surface stabilization and ligand-mediated activation, whereas TrkAIII exhibits GA-sensitive interactions with Hsp90 required for spontaneous activity and to a lesser extent stability. We show that GA inhibits proliferation and induces apoptosis of TrkAI expressing NB cells, whereas TrkAIII reduces the sensitivity of NB cells to GA-induced elimination. Our data suggest that GA-sensitive interactions with Hsp90 are critical for both TrkAI tumour suppressor and TrkAIII oncogenic function in NB and that TrkAIII expression exerts a negative impact on GA-induced NB cell eradication, which can be counteracted by a novel TrkAIII-specific peptide nucleic acid inhibitor.


Subject(s)
Benzoquinones/pharmacology , HSP90 Heat-Shock Proteins/metabolism , Lactams, Macrocyclic/pharmacology , Neuroblastoma/metabolism , Receptor, trkA/metabolism , Alternative Splicing , Antigens, Surface/metabolism , Enzyme Stability/drug effects , Genes, Tumor Suppressor/drug effects , Genes, Tumor Suppressor/physiology , Humans , Isoenzymes/metabolism , Isoenzymes/physiology , Neuroblastoma/genetics , Neuroblastoma/pathology , Oncogenes/drug effects , Oncogenes/physiology , Phosphorylation/drug effects , Protein Binding/drug effects , Protein Kinase Inhibitors/pharmacology , Protein Transport/drug effects , Receptor, trkA/antagonists & inhibitors , Receptor, trkA/genetics , Receptor, trkA/physiology , Transfection , Tumor Cells, Cultured , Tyrosine/metabolism
8.
Eur J Cancer ; 39(13): 1927-35, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12932673

ABSTRACT

Two bona fide c-Src inhibitors, denominated CGP77675 and CGP76030, reduced in a time- and concentration-dependent manner (i) the proliferation of the PC3 prostate carcinoma cell line, as assessed by the [3H]-thymidine incorporation test, (ii) the capacity of PC3 cells to adhere and spread on Matrigel substrate, as determined by crystal violet staining, (iii) the ability of PC3 cells to migrate through a gelatine boundary and invade a Matrigel substrate. The latter effect was not due to a decrease of urokinase-type plasminogen activator (uPA), nor of metalloproteinase-2 (MMP-2) activities. The MMP-9 activity, along with the expression of the Tissue Inhibitor of Metalloproteinases (TIMP)-1 and TIMP-2, were reduced by the two inhibitors, consistent with the ability of c-Src to enhance MMP-9 and TIMP expression levels. Collectively, these data demonstrate that the pyrrolopyrimidine-derived c-Src inhibitors significantly reduced PC3 cell activities associated with their malignant phenotype.


Subject(s)
Antineoplastic Agents/therapeutic use , Prostatic Neoplasms/drug therapy , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , src-Family Kinases/antagonists & inhibitors , Apoptosis , Blotting, Western , CSK Tyrosine-Protein Kinase , Cell Adhesion/drug effects , Cell Division/drug effects , Cell Movement/drug effects , Cell Size , Drug Screening Assays, Antitumor , Humans , Male , Matrix Metalloproteinases/metabolism , Neoplasm Invasiveness , Protein-Tyrosine Kinases/antagonists & inhibitors , Tumor Cells, Cultured/drug effects
9.
Eur J Biochem ; 268(2): 405-13, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11168376

ABSTRACT

Thioredoxin (Trx) inhibited tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 activity with an approximate IC50 of 0.3 microM, matrix metalloproteinase (MMP)-2 activity with an approximate IC50 of 2 microM but did not inhibit MMP-9 activity. This differential capacity of Trx to inhibit TIMP and MMP activity resulted in the promotion of MMP-2 and MMP-9 activity in the presence of molar TIMP excess. Inhibition of TIMP and MMP-2 activity by Trx was dependent upon thioredoxin reductase (TrxR), was abolished by Trx catalytic site mutation and did not result from TIMP or MMP-2 degradation. HepG2 hepatocellular carcinoma cells induced to secrete Trx inhibited TIMP activity in the presence of TrxR. SK-N-SH neuroblastoma cells secreted TrxR, which inhibited TIMP and MMP-2 activity in the presence of Trx. Trx stimulated SK-N-SH invasive capacity in vitro in the absence of exogenous TrxR. This study therefore identifies a novel extracellular role for the thioredoxin/thioredoxin reductase redox system in the differential inhibition of TIMP and MMP activity and provides a novel mechanism for altering the TIMP/MMP balance that is of potential relevance to tumor invasion.


Subject(s)
Matrix Metalloproteinase Inhibitors , Neoplasm Invasiveness , Neuroblastoma/pathology , Thioredoxins/pharmacology , Tissue Inhibitor of Metalloproteinases/antagonists & inhibitors , Disulfides/metabolism , Humans , Matrix Metalloproteinase 9/metabolism , Neoplasm Proteins/metabolism , Neoplasm Proteins/pharmacology , Thioredoxin-Disulfide Reductase/metabolism , Thioredoxins/metabolism , Tissue Inhibitor of Metalloproteinase-1/antagonists & inhibitors , Tissue Inhibitor of Metalloproteinase-2/antagonists & inhibitors , Tumor Cells, Cultured
10.
Int J Cancer ; 86(2): 188-96, 2000 Apr 15.
Article in English | MEDLINE | ID: mdl-10738245

ABSTRACT

bcl-2 expression is often associated with poor prognosis in several types of tumors; however, the role of this molecule in breast cancer is still controversial. We found earlier that over-expression of bcl-2 in a human breast-cancer cell line (MCF7(ADR)) enhances its tumorigenicity and metastatic potential by inducing metastasis-associated properties such as increased secretion of the matrix metalloproteinase-9 (mmp-9). In the present study, we investigated the effect of bcl-2 over-expression on the activity of the transcription factor NF-kappaB, an important regulator of genes involved in tumor progression and invasion. Transient transfection experiments indicate that over-expression of bcl-2 in the MCF7(ADR) cell line, enhances NF-kappaB-dependent transcriptional activity. Mobility-shift analysis revealed an increase of NF-kappaB DNA-binding in bcl-2-over-expressing clones that correlated with lower levels of the NF-kappaB cytoplasmic inhibitor IkappaBalpha. Moreover, point mutations of 2 highly conserved residues within the BH1 and BH2 domains that abrogate the interaction of bcl-2 with bax, or deletion of the N-terminal BH4 domain, completely eliminate the ability of this molecule to up-regulate NF-kappaB-dependent transactivation. Since mmp-9 is a NF-kappaB-regulated gene, we also investigated whether bcl-2 over-expression up-regulated mmp-9 transcription. We found that induction of mmp-9 mRNA correlates with the activation of an mmp-9-promoter-reporter-gene construct in transient transfection assay, and a mutation of the (-600)mmp-9-NF-kappaB binding element abolishes this effect. The overall data indicate that bcl-2-mediated regulation of NF-kappaB-transcription-factor activity may represent an important mechanism for the promotion of malignant behavior in MCF-7(ADR) cells.


Subject(s)
Breast Neoplasms/metabolism , Gene Expression , Genes, bcl-2 , I-kappa B Proteins , Matrix Metalloproteinase 9/genetics , NF-kappa B/metabolism , Transcription, Genetic , Binding Sites , Breast Neoplasms/genetics , DNA/metabolism , DNA-Binding Proteins/metabolism , Humans , NF-KappaB Inhibitor alpha , NF-kappa B/antagonists & inhibitors , Point Mutation , Proto-Oncogene Proteins c-bcl-2/physiology , RNA, Messenger/biosynthesis , Transfection , Tumor Cells, Cultured
11.
Scand J Clin Lab Invest ; 59(3): 233-7, 1999 May.
Article in English | MEDLINE | ID: mdl-10400168

ABSTRACT

The visible absorption spectrum of oxyhaemoglobin depends on its content of foetal haemoglobin and on the pH of the blood. These variables are known to affect oxygen saturation readings measured by the OSM3 Hemoximeter. As the hemoximeter estimates foetal haemoglobin content from the absorption spectrum of oxyhaemoglobin, this estimation is affected by pH. We quantified the effect of pH on oxyhaemoglobin reading in order to calculate a correction factor to adjust for pH. We manipulated a pool of fresh heparinized cord blood samples to produce a range of pH values from 6.99-7.53 in fully oxygenated blood with a carbon dioxide tension of 5.3 kPa. We measured oxygen saturation and percent foetal haemoglobin using an OSM3 Hemoximeter and pH with a linked blood gas analyser. The effect of pH on readings of saturation and fractional foetal haemoglobin was confirmed and a correction factor was calculated. The value of KHbF, the coefficient used in the OSM3 Hemoximeter to estimate the amount of fractional foetal haemoglobin present in a sample, was determined to be 18.3, which slightly but significantly differed (p = 0.04) from the 18.6 used by the OSM3 Hemoximeter. An equation was derived to correct the errors made by pH on the saturation measurement of oxygenated blood.


Subject(s)
Fetal Hemoglobin/metabolism , Hydrogen-Ion Concentration , Oximetry/methods , Oxyhemoglobins/analysis , Adult , Blood Gas Analysis , Carbon Dioxide/blood , Female , Fetal Blood , Fetal Hemoglobin/analysis , Humans , Oximetry/instrumentation , Oximetry/standards , Oxyhemoglobins/metabolism , Pregnancy , Reproducibility of Results
12.
Cell Growth Differ ; 10(5): 353-67, 1999 May.
Article in English | MEDLINE | ID: mdl-10359016

ABSTRACT

Spontaneous epithelial (S) to neuroblast (N) conversion enhanced the capacity of SK-N-SH neuroblastoma (NB) cells to invade reconstituted basement membrane in vitro. This involved a switch to matrix metalloproteinase (MMP) activity, in particular MMP-9, and was associated with the induction of MMP-9 expression. N-type-specific MMP-9 expression was herbimycin A inhibitable tyrosine kinase (possibly c-src) dependent and was regulated transcriptionally through GT-box (-52), and nuclear factor kappaB (NFkappaB; -600) elements within the MMP-9 gene. GT-box function was associated with elevated levels of specific nuclear GT-box binding complexes in N-type cells. NFkappaB function was associated with specific p50- and p65-containing nuclear NFkappaB binding complex(es). No function could be attributed to the proximal AP-1 (-79) element, and minimal function was attributed to the SP-1 (-560), ets (-540), or distal AP-1 (-533) elements. This was despite elevated levels of specific junD/fra-1 containing proximal AP-1 element binding complex(es) in N-type cells. Our data highlight a pivotal role for the GT-box, in concert with the NFkappaB element, in the transcriptional up-regulation of MMP-9 expression during spontaneous S to N phenotype conversion by SK-N-SH cells involved in enhanced basement membrane invasivity.


Subject(s)
Collagenases/genetics , NF-kappa B/metabolism , Neoplasm Invasiveness , Neuroblastoma/pathology , Neurons/cytology , Transcription, Genetic , Up-Regulation , Benzoquinones , Binding Sites , CSK Tyrosine-Protein Kinase , Cell Extracts , Cell Nucleus/metabolism , Collagenases/physiology , Enzyme Inhibitors/pharmacology , Epithelial Cells , Humans , Lactams, Macrocyclic , Matrix Metalloproteinase 9 , Phenotype , Promoter Regions, Genetic , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/metabolism , Quinones/pharmacology , Response Elements , Rifabutin/analogs & derivatives , Sp1 Transcription Factor/metabolism , Transcription Factor AP-1/metabolism , Transcriptional Activation , Tumor Cells, Cultured , src-Family Kinases
13.
Cancer Res ; 58(14): 2957-60, 1998 Jul 15.
Article in English | MEDLINE | ID: mdl-9679953

ABSTRACT

The degradation of tissue inhibitor of metalloproteinase (TIMP)-free matrix metalloproteinase (MMP)-2 to proteolytically inactive fragments by plasmin was inhibited in equimolar mixtures of purified TIMP-2 and TIMP-free MMP-2 and was not observed in purified MMP-2-TIMP-2 complexes. Divalent cation chelators EDTA and sodium Alendronate did not inhibit plasmin degradation of TIMP-free MMP-2 but reversed the ability of TIMP-2 to protect MMP-2 from degradation by plasmin. Our data confirm a role for plasmin in the clearance of TIMP-free MMP-2, identify a pivotal role for TIMP-2 in regulating MMP-2 longevity in plasmin-containing environments, and highlight a novel therapeutic use for chelators of divalent cations, including the bisphosphonate Alendronate, in the reversal of TIMP-2 protection of MMP-2 from degradation by plasmin. We propose that these observations are relevant to pathologies that are dependent upon plasmin and MMP-2 activity (e.g., tumor invasion and metastasis).


Subject(s)
Fibrinolysin/antagonists & inhibitors , Gelatinases/drug effects , Metalloendopeptidases/drug effects , Protease Inhibitors/pharmacology , Tissue Inhibitor of Metalloproteinase-2/pharmacology , Alendronate/pharmacology , Cations , Chelating Agents/pharmacology , Diphosphonates/pharmacology , Edetic Acid/pharmacology , Fibrinolysin/metabolism , Gelatinases/metabolism , Humans , Matrix Metalloproteinase 2 , Metalloendopeptidases/metabolism , Tumor Cells, Cultured/drug effects
14.
Int J Cancer ; 77(1): 82-93, 1998 Jul 03.
Article in English | MEDLINE | ID: mdl-9639398

ABSTRACT

We show that osteopontin (OPN), bone sialoprotein (BSP) and GRGDSP peptides, in solution, induce activation of metalloproteinase-2 (MMP-2) secreted by human GCT23 giant cell tumour cells. Activation of MMP-2 is RGD sequence dependent, possibly involves anti-alphaVbeta3 integrins, is preceded by a change from spread to rounded cell morphology and is mimicked by the actin depolymerising agent cytochalasin B. Cells that had spread on OPN, BSP and GRGDSP substrata failed to activate MMP-2, but subsequent addition of soluble GRGDSP induced rounding and MMP-2 activation. Activation induced by GRGDSP and cytochalasin B was cell mediated, inhibited by EDTA, tissue inhibitor of metalloproteinase-2 (TIMP-2) and carboxyl terminal MMP-2 consistent with a role for membrane type (MT)-MMP but did not involve urokinase, plasmin or thrombin activity. Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2. GRGDSP and cytochalasin B enhanced levels of membrane-associated pro- and active form MMP-1 and MMP-2 but not MT-MMP-1, stimulated cell surface MMP-1 staining and induced that of MT-MMP-1, MMP-2 and TIMP-2. This was consistent with the possible relocation of constitutive MT-MMP-1 to the cell surface as a prerequisite for subsequent cell surface MMP-2/TIMP-2/MT-MMP-1 complex formation and to the potential induction of conditions favourable for reciprocal cell surface MMP-1/MMP-2 activation. Our data provide a novel insight into interactions between RGD containing bone matrices, GCT cells and MMPs of potential relevance to GCT pathology.


Subject(s)
Carcinoma, Giant Cell/enzymology , Gelatinases/metabolism , Metalloendopeptidases/metabolism , Oligopeptides/genetics , Oligopeptides/pharmacology , Sialoglycoproteins/pharmacology , Carcinoma, Giant Cell/genetics , Carcinoma, Giant Cell/pathology , Cell Size/drug effects , Cell Size/genetics , Enzyme Activation/drug effects , Enzyme Activation/genetics , Gene Expression Regulation, Neoplastic/drug effects , Humans , Integrin-Binding Sialoprotein , Matrix Metalloproteinase 2 , Osteopontin , Tumor Cells, Cultured
15.
Int J Cancer ; 75(5): 721-30, 1998 Mar 02.
Article in English | MEDLINE | ID: mdl-9495240

ABSTRACT

Transforming growth factor-beta (TGFbeta1) enhances human MDA-MB-231 breast tumour cell invasion of reconstituted basement membrane in vitro but does not inhibit proliferation of this cell line. In contrast to basal invasion, which is plasmin-, urokinase (uPA)-, tissue-type plasminogen activator (t-PA)-, matrix metalloproteinase (MMP)-9- and TIMP-1-inhibitable MMP-dependent, TGFbeta1 enhanced-invasion is dependent upon plasmin and uPA activity but does not appear to involve t-PA-, MMP9- or TIMP-1-inhibitable MMPs, as judged by inhibitor studies. Enhanced invasion is associated with increased u-PA, UPAR, PAI-1, MT-MMP-1, MMP-9 and TIMP-1 expression; with reduced t-PA, MMP-1 and MMP-3 expression; and with the induction of membrane MMP-9 association. The net result of these changes includes increased secreted, but not membrane-associated, uPA levels and activity and reduced secreted levels of plasmin and APMA-activatable gelatinolytic, collagenolytic and caseinolytic MMP activity but no change in membrane-associated gelatinolytic activity, despite increased MT-MMP-1 expression and MMP-9 membrane association. TGFbeta1 does not induce MMP-2 expression. Our data indicate that TGFbeta1 can promote the malignant behaviour of MDA-MB-231 cells refractory to TGFbeta1-mediated proliferation control by enhancing their invasive capacity. We suggest that this results from the action of a uPA/plasmin-dependent mechanism resulting from stimulation of uPA expression, secretion and subsequent activity, despite elevated PAI-1 inhibitor levels.


Subject(s)
Breast Neoplasms/pathology , Neoplasm Invasiveness , Transforming Growth Factor beta/pharmacology , Urokinase-Type Plasminogen Activator/metabolism , Breast Neoplasms/enzymology , Caseins/metabolism , Collagen/metabolism , Drug Combinations , Humans , Laminin , Matrix Metalloproteinase 3/metabolism , Plasminogen Activator Inhibitor 1/metabolism , Proteoglycans , Receptors, Transforming Growth Factor beta/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism , Up-Regulation
16.
Int J Cancer ; 73(5): 740-8, 1997 Nov 27.
Article in English | MEDLINE | ID: mdl-9398056

ABSTRACT

Al-trans retinoic acid (RA) enhanced human, S-type, SK-N-SH neuroblastoma cell invasion of reconstituted basement membrane in vitro but did not induce terminal differentiation of this cell line. In contrast to basal invasion, which was urokinase (uPA)- and plasmin-dependent, RA-enhanced invasion was dependent on tissue-type plasminogen activator (t-PA) and plasmin activity. Neither basal nor RA-enhanced invasion involved TIMP-2 inhibitable metalloproteinases. Enhanced invasion was associated with the induction of t-PA expression, increased expression of the putative t-PA receptor amphoterin, increased association of t-PA with cell membranes and increased net membrane-associated PA activity. Enhanced invasion was not associated with significant changes in the expression of uPA or its membrane receptor UPAR; plasminogen activator inhibitors PAI-1 and PAI-2; metalloproteinases MMP-1, MMP-2, MMP-3, MMP-9 and membrane type MMP1; or tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2. RA stimulated the association of t-PA with the external cell membrane surface, which could be inhibited by heparin sulphate but not by mannose sugars or chelators of divalent cations, consistent with a role for amphoterin. Our data indicate that RA can promote the malignant behavior of S-type neuroblastoma cells refractory to RA-mediated terminal differentiation by enhancing their basement membrane invasive capacity. We suggest that this results from the action of a novel, RA-regulated mechanism involving stimulation of t-PA expression and its association with the cell membrane leading to increased PA-dependent matrix degradation.


Subject(s)
Antineoplastic Agents/pharmacology , Neuroblastoma/pathology , Tissue Plasminogen Activator/metabolism , Tretinoin/pharmacology , Basement Membrane/drug effects , Basement Membrane/metabolism , Basement Membrane/pathology , Biocompatible Materials , Brain-Derived Neurotrophic Factor/metabolism , Cell Division/drug effects , Collagen , Drug Combinations , Humans , Laminin , Metalloendopeptidases/metabolism , Neoplasm Invasiveness , Neuroblastoma/metabolism , Phenotype , Plasminogen Activator Inhibitor 1/metabolism , Plasminogen Activator Inhibitor 2/metabolism , Proteoglycans , Receptor Protein-Tyrosine Kinases/metabolism , Receptor, trkB , Receptors, Nerve Growth Factor/metabolism , Tissue Inhibitor of Metalloproteinases/metabolism , Tumor Cells, Cultured
17.
Cell Growth Differ ; 8(7): 789-800, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9218873

ABSTRACT

In this study, the regulatory elements involved in ICAM-1 transcriptional response to phorbol ester (12-0-tetradecanoylphorbol-13-acetate; TPA) have been investigated in the human neuroblastoma cell line, SK-N-SH. TPA induced intercellular adhesion molecule 1 (ICAM-1) protein expression in SK-N-SH cells within 24 h of treatment as judged by indirect immunofluorescence. Basal ICAM-1 mRNA levels were barely detectable in untreated SK-N-SH cells but were induced by TPA to a maximal level with 4 h and were reduced thereafter. Analysis of the 5' promoter sequence of ICAM-1 revealed two regions that functioned equally in the TPA induction of ICAM-1 transcription. The first region (-145 to -227) contained a nuclear factor-kappa B (NF kappa B) element. The second region (-316 to -390) contained a putative TPA-responsive element (TRE; TGATTCA) and a TATA box. Deletion and point mutation of the latter region indicated that the TRE was indeed the functional element within this region and acted fully and independently of all other elements including the TATA box at position -352. This TRE bound TPA induced specific nuclear complexes in vitro containing junD, c-jun, c-fos, and fra2 but not cAMP-responsive element binding/activating transcription factor family proteins. ICAM-TRE binding activity was induced within 30 min following TPA treatment. This preceded the appearance of ICAM-NF kappa B site binding activity. Cotransfection of c-jun and c-fos expression vectors into SK-N-SH cells induced transactivation from ICAM-1 promoter constructs containing the intact but not mutated TRE site. Primer extension analyses revealed that TPA had induced transcription exclusively at two sites -40 and -41 bp upstream of the translation start site. These data show that the ICAM-TRE and its cognate jun- and fos-containing transcription factors play a predominant role in the transcriptional response of ICAM-1 to the protein kinase C activator TPA in SK-N-SH cells.


Subject(s)
Intercellular Adhesion Molecule-1/genetics , Neuroblastoma/genetics , Regulatory Sequences, Nucleic Acid/genetics , Tetradecanoylphorbol Acetate/pharmacology , Transcription Factor AP-1/metabolism , Transcriptional Activation/genetics , Cyclic AMP Response Element-Binding Protein/metabolism , DNA, Neoplasm/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Neoplastic/genetics , Humans , NF-kappa B/metabolism , Protein Binding , Proto-Oncogene Proteins c-fos/metabolism , Proto-Oncogene Proteins c-jun/biosynthesis , Proto-Oncogene Proteins c-jun/metabolism , RNA, Messenger/analysis , TATA Box/genetics , Transcription, Genetic/genetics , Transcriptional Activation/drug effects
18.
Invasion Metastasis ; 17(5): 240-50, 1997.
Article in English | MEDLINE | ID: mdl-9876218

ABSTRACT

Cloned v-raf, v-raf/v-myc, and spontaneously transformed rat liver epithelial (RLE) cell lines were examined for meastatic capability in nude mice, using the LacZ gene as a marker for quantitation of micrometastases. Six cloned lines (R3611-T lines) derived from nude mouse xenografts of the v-raf transformed R3611-3 cells displayed variable metastatic capabilities. Three of six subcutaneously inoculated R3611-TlacZ lines produced spontaneous lung metastasis in nude mice. One of the lines, R3611-T2lacZ was highly efficient at metastatic conversion and produced more lung colonies than a faster growing v-raf/v-myc-transformed RJ2-14lacZ line. The spontaneously transformed RLElacZ line (C4T) was nonmetastatic, although it produced larger subcutaneous tumors than the metastatic R3611-T2lacZ line. Metastatic conversion correlated with upregulation of urokinase-type plasminogen activator receptor RNA expression and downregulation of plasminogen activator inhibitor-1, collagen alpha1 (I), and cytokeratin 14 (K14) RNA expression. These findings indicate that proteolytic activities associated with plasminogen activation play a role in the metastatic development in this model. Decreased production of extracellular proteins and cytoskeletal changes associated with lack of K14 expression are also likely to have contributed to the metastatic conversion of the RLE transformants.


Subject(s)
Cell Transformation, Neoplastic/genetics , Genes, myc , Liver Neoplasms, Experimental/pathology , Liver/cytology , Lung Neoplasms/secondary , Retroviridae Proteins, Oncogenic/genetics , Animals , Clone Cells , Collagen/genetics , Collagen/metabolism , Down-Regulation , Epithelial Cells/pathology , Gene Expression Regulation, Neoplastic , Keratin-14 , Keratins/metabolism , Liver Neoplasms, Experimental/genetics , Lung Neoplasms/pathology , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Oncogene Proteins v-raf , Phenotype , Plasminogen Activator Inhibitor 1/genetics , Plasminogen Activator Inhibitor 1/metabolism , RNA, Messenger/analysis , Rats , Rats, Inbred F344 , Receptors, Cell Surface/genetics , Receptors, Cell Surface/metabolism , Receptors, Urokinase Plasminogen Activator
19.
Biotechniques ; 21(5): 904-9, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8922633

ABSTRACT

Matrigel, a basement membrane (BM) extract of the Engelbreth-Holm-Swarm (EHS) sarcoma, used in tumor invasion assays, was found to contain plasminogen. Plasminogen was identified, using Western blot analysis and casein zymograms, by comparison with human plasminogen. matrigel contained approximately 20-100 ng of plasminogen per 100 micrograms of protein as determined by these assays. Matrigel reconstitution and incubation at 37 degrees C caused activation of plasminogen, which was serine protease dependent and involved tissue plasminogen activator (tPA) as an anti-tPA antibody which inhibited activation. This reconstitution and incubation also caused leupeptin-inhibitable degradation of Matrigel components as assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Degradation of the BM extract copolymerized in zymograms was caused by human plasminogen and plasminogen in the Matrigel. Maximal plasmin activity, following incubation of Matrigel at 37 degrees C for 16 h, was equivalent to approximately 10 ng of purified plasmin using the plasmin substrate D-Val-Leu-Lys p-nitroanilide. matrigel, therefore, contained all the components of the plasmin-generating system, including plasminogen. The plasmin generated degraded Matrigel components and exogenous substrates. Our data suggest that, since this tumor BM acts as a reservoir for enzymes of the plasmin-generating system, caution should be taken by investigators interpreting data concerning the effects of Matrigel on cell behavior and, in particular, cellular invasion.


Subject(s)
Collagen/analysis , Laminin/analysis , Plasminogen/analysis , Proteoglycans/analysis , Basement Membrane/chemistry , Drug Combinations , Fibrinolysin/metabolism , Humans
20.
Int J Cancer ; 69(5): 386-93, 1996 Oct 21.
Article in English | MEDLINE | ID: mdl-8900372

ABSTRACT

We have examined the expression of 2 tumor-associated metalloproteinases, MMP-2 and MMP-9, in 48 primary cultures of prostatic carcinoma (PRCA) and 33 cultures of benign prostatic hyperplasia (BPH). PRCA cultures secrete significantly more MMP-9 than their benign counterparts. Secreted MMP-2 did not differ significantly in cultures but was lower in PRCA cultures. Two cultures of benign origin exhibited high MMP-9 secretion and growth patterns consistent with a malignancy. Both cases were followed and successively re-evaluated histologically and rediagnosed as organ-confined PRCA. MMP expression in culture may be of predictive value in the identification of incidental PRCA. MMP-9 secretion and its ratio with MMP-2 were highest in epithelial cultures from invasive, metastatic tumors when compared both to disease confined to prostate gland and to locally extensive disease. MMP-9 secretion was greatest also in cultures derived from tissues of high Gleason histological grade. Active MMP-9 species were detected in 15 cultures (31%) of PRCA. Active MMP-2 species were observed in cultures of both BPH and PRCA origin in almost the same amounts. Although average levels were not significantly different, as a ratio to proform species, a significant elevation was observed in cultures of PRCA origin. We propose, therefore, that an elevated expression of MMP-9 and a high ratio of MMP-9 to MMP-2 in short-term prostate epithelial cultures is of potential diagnostic and prognostic significance.


Subject(s)
Metalloendopeptidases/metabolism , Prostatic Neoplasms/diagnosis , Diagnosis, Differential , Dose-Response Relationship, Drug , Epidermal Growth Factor/pharmacology , Epithelium/metabolism , Humans , Male , Metalloendopeptidases/analysis , Metalloendopeptidases/drug effects , Neoplasm Staging , Prostatic Neoplasms/classification , Prostatic Neoplasms/enzymology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...